1-3 of 3
Josh Lehrer, MD MPhil, FACC
Close
Sort by
Journal Articles

Impact of GBT440 on Unconjugated Bilirubin and Jaundice in Sickle Cell Disease: A Patient Case Report

Paul Telfer, FRCPath, MD, Josh Lehrer, MD MPhil, FACC, Irene Agodoa, MD, Marzena Jurek, MS, Kathleen M Fox, PhD, Laurie Burke, BPharm, MPH, Noel Landsman, Dip.Nur (SA), Timothy Mant, MB, FFPM, FRCP
Journal: Blood
Blood (2017) 130 (Supplement 1): 4779.
https://doi.org/10.1182/blood.V130.Suppl_1.4779.4779
Published: 2017
Journal Articles

The Pharmacokinetics (PK) of GBT440 Following Single Doses in Pediatric Patients with Sickle Cell Disease (SCD)

Carla B Washington, PhD, Michelle Green, PhD, Adlette C. Inati, MD, Clark Brown, MD PhD, Carolyn C Hoppe, MD, Winfred Wang, MD, Ganesh Balaratnam, MD, Sandra Dixon, MS, Erica Fong, Athiwat Hutchaleelaha, PhD, Margaret E Tonda, PharmD, Josh Lehrer, MD MPhil, FACC
Journal: Blood
Blood (2017) 130 (Supplement 1): 980.
https://doi.org/10.1182/blood.V130.Suppl_1.980.980
Published: 2017
Journal Articles

Initial Results from a Cohort in a Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor

Carolyn C Hoppe, MD, Adlette C. Inati, MD, Clark Brown, MD PhD, Winfred Wang, MD, Victor R. Gordeuk, MD, Robert Liem, MD, Gerald Woods, MD, Connie M. Piccone, MD, Erica Fong, Ganesh Balaratnam, MD, Sandy Dixon, Margaret E Tonda, PharmD, Carla B Washington, PhD, Yifah Yaron, MD PhD, Josh Lehrer, MD MPhil, FACC
Journal: Blood
Blood (2017) 130 (Supplement 1): 689.
https://doi.org/10.1182/blood.V130.Suppl_1.689.689
Published: 2017